Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

Core Insights - Krystal Biotech, Inc. will host an investor conference call on January 8, 2026, at 4:30 pm ET to discuss an interim clinical update from the CORAL-1 study evaluating KB407 for cystic fibrosis [1] - The update will focus on results from the highest dose cohort and include molecular assessments of KB407 transduction and CFTR protein expression [1] Company Overview - Krystal Biotech, Inc. is a global biotechnology company focused on developing genetic medicines for diseases with high unmet medical needs [3] - The company's first commercial product, VYJUVEK, is the first redosable gene therapy approved in the US, Europe, and Japan for dystrophic epidermolysis bullosa [3] - The company is advancing a pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics [3]